Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Passage Bio, a clinical-stage genetic medicines company, has granted inducement awards to new employees, consisting of options to purchase 79,600 shares of common stock at an exercise price of $1.69 per share. This price reflects the stock's closing value on May 16, 2022. The options will vest over four years, with 25% vesting after one year. Passage Bio's focus is on developing therapies for central nervous system disorders, with ongoing clinical programs in GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia.
- Granted options to purchase 79,600 shares, aligning employee interests with company performance.
- The exercise price of $1.69 per share reflects the market rate, ensuring fair compensation.
- Ongoing clinical programs targeting CNS disorders with significant unmet needs.
- None.
PHILADELPHIA, May 20, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees.
Passage Bio granted options to purchase 79,600 shares of common stock to these employees as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of
The shares subject to the Inducement Options will vest over four years, with 25 percent of the shares vesting on the one-year anniversary of the applicable grant date, and the remainder vesting in 36 equal monthly installments thereafter, subject to each employee’s continued employment. The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Passage Bio Investors:
Stuart Henderson
Passage Bio
267-866-0114
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
MikeBeyer@sambrown.com
FAQ
What are the recent developments for Passage Bio (PASG) in May 2022?
How long will the stock options at Passage Bio (PASG) vest?
What is the focus of Passage Bio (PASG) in the biotech industry?
What clinical programs is Passage Bio (PASG) currently advancing?
What is the significance of the stock options granted by Passage Bio (PASG)?
